Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Will Fold Antibody Developer Domantis Into Biopharmaceutical CEDD

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK will pay $454 mil. to acquire Domantis’ technology for unconventional administration of monoclonal antibodies.

You may also be interested in...



Follow-On Biologics Market Unfolding: Big Pharma Signals An Interest

Large pharmaceutical and biotechnology companies will start openly developing follow-on biologics once Congress passes legislation authorizing an abbreviated approval pathway, Cowen & Co. analyst Ken Cacciatore predicted

Follow-On Biologics Market Unfolding: Big Pharma Signals An Interest

Large pharmaceutical and biotechnology companies will start openly developing follow-on biologics once Congress passes legislation authorizing an abbreviated approval pathway, Cowen & Co. analyst Ken Cacciatore predicted

GSK’s Witty Looks To Biotech Model In R&D Retool; Mini Labs Will Bid For Project Funding

Planned units include five to 80 scientists, operate within the CEDDs program.

Related Content

Topics

UsernamePublicRestriction

Register

PS063654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel